You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《美股業績》輝瑞(PFE.US)首季多賺61% 維持今年新冠口服藥銷售額預測
阿思達克 05-04 09:04
輝瑞(PFE.US)公佈今年首季盈利增長61%至78.64億美元,調整後每股盈利爲1.67美元,超出市場預期的0.2美元,受惠於新冠疫苗銷售達132億美元,高於分析師估計的106億美元。收入則上升77%,至256.61億美元。 輝瑞維持今年新冠口服藥Paxlovid銷售額爲220億美元的預測不變,不及市場預期的261億美元,同時還重申全年新冠疫苗銷售預測爲320億美元,因雖然部分地區的確診病例有所增加,但部分國家已經放寬防疫措施。 輝瑞預計將在6月初前向美國監管機構提交數據,以支持對5歲以下兒童的三劑疫苗方案的緊急授權。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account